查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1370934

肺動脈高壓市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按藥物類別、類型、給藥途徑、地區、競爭細分

Pulmonary Arterial Hypertension Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Class, By Type, By Route of Administration, By Region, Competition
出版日期: | 出版商: TechSci Research | 英文 170 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022年，全球肺動脈高壓（PAH）市場估值達66.6億美元，預計在整個預測期內將大幅成長，預計年複合成長率（CAGR）為5.32%，預計透過2020年將達到90.6億美元。 2028. 肺動脈高血壓是一種罕見但嚴重的疾病，其特徵是肺動脈血壓升高，肺動脈將血液從心臟輸送到肺部。這種情況會導致這些動脈變窄和僵硬，增加心臟的壓力，並可能導致心臟衰竭。

全球肺動脈高壓 (PAH) 市場包括旨在管理和解決 PAH 的各種藥品、醫療器材和治療策略。醫學理解、創新療法和對 PAH 認知的最新發展是該市場成長的關鍵驅動力。促成這一成長的因素包括久坐生活方式和肥胖等危險因素導致多環芳烴患病率不斷上升，以及患者和醫療保健專業人員診斷能力的提高和認知的提高。

藥物介入在治療 PAH 方面發揮關鍵作用，藥物針對與疾病發病機制相關的特定途徑。這些藥物，如前列環素類似物、內皮素受體拮抗劑和 5 型磷酸二酯酶抑制劑，旨在擴張血管、降低動脈壓並緩解疲勞和呼吸急促等症狀。

市場概況
預測期 2024-2028
2022 年市場規模 66.6億美元
2028 年市場規模 90.6億美元
2023-2028 年年複合成長率 5.32%
成長最快的細分市場 磷酸二酯酶5
最大的市場 北美洲

此外，肺血管擴張幫浦等醫療設備和心室輔助裝置等植入設備有助於治療嚴重的肺動脈高壓病例。除了傳統療法外，還建議改變生活方式和定期鍛煉，以提高患者的生活品質。然而，多環芳烴市場仍存在挑戰，包括治療費用高昂和獲得專業護理的機會有限。此外，PAH 診斷的複雜性和對專業知識的需求可能會阻礙及時介入。

主要市場促進因素

  • 1. PAH 盛行率和認知不斷提高：PAH 盛行率不斷上升，對其嚴重性的認知不斷提高，推動了 PAH 市場的擴張。公共衛生運動、改善的醫學教育和患者倡導活動有助於早期診斷和介入。
  • 2.創新的治療方法：針對PAH潛在機制的藥物進步已經改變了治療格局。創新藥物和醫療設備正在改善患者的治療結果和生活品質。
  • 3.個人化醫療：根據患者個別情況量身訂做醫療服務是重要趨勢。基因檢測、分子分析和標靶治療可最佳化治療效果和患者參與度。

主要市場挑戰

  • 1.高昂的治療費用：PAH 藥物、醫療設備和專業護理的費用給患者和醫療保健系統帶來了財務挑戰。獲得有效治療和綜合護理的機會可能會受到影響。
  • 2.認知有限：患者和醫療保健專業人員缺乏認知會導致診斷延遲、護理欠佳和研究經費有限。透過教育和宣傳提高認知至關重要。
  • 3.關鍵藥物的專利到期：專利到期影響治療的可近性、可負擔性和創新性。在患者獲得負擔得起的治療與藥物創新之間取得平衡至關重要。

主要市場趨勢

  • 1.合作研究和全球網路：國際夥伴關係和網路促進知識交流、跨學科方法以及加速創新療法和治療指南的發展。
  • 2.個人化治療方法：由遺傳學和分子譜驅動的個人化醫療正在改變 PAH 護理。精確的診斷和標靶治療可提高治療效果並增強患者的能力。

細分市場洞察

  • 1.藥物類別洞察：磷酸二酯酶 5 抑制劑，如西地那非和他達拉非，由於能夠鬆弛​​肺血管和緩解症狀，在 PAH 市場中佔據主導地位。
  • 2.類型見解：儘管有學名藥，但具有既定療效和安全記錄的品牌藥物仍然是 PAH 治療的主要選擇。

區域洞察

由於先進的醫療基礎設施、強大的研究計劃和監管支持，北美在 PAH 市場中處於領先地位。醫療機構之間的合作、宣傳活動和患者宣傳工作有助於改善該地區的疾病管理和結果。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球肺動脈高壓市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依藥物類別（前列環素和前列環素類似物、鈣通道阻斷劑、磷酸二酯酶 5、內皮素受體拮抗劑等）
    • 按類型（品牌、學名藥）
    • 依給藥途徑（口服、靜脈/皮下、吸入）
    • 按公司分類 (2022)
    • 按地區
  • 市場地圖

第 6 章：北美肺動脈高壓市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按藥物類別
    • 按類型
    • 依給藥途徑
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 7 章：歐洲肺動脈高壓市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按藥物類別
    • 按類型
    • 依給藥途徑
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第 8 章：亞太地區肺動脈高壓市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按藥物類別
    • 按類型
    • 依給藥途徑
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第 9 章：南美洲肺動脈高壓市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按藥物類別
    • 按類型
    • 依給藥途徑
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲肺動脈高壓市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按藥物類別
    • 按類型
    • 依給藥途徑
    • 按國家/地區
  • MEA：國家分析
    • 南非 肺動脈高壓
    • 沙烏地阿拉伯 肺動脈高壓
    • 阿拉伯聯合大公國肺動脈高壓

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 最近的發展
  • 產品發布
  • 併購

第 13 章：大環境分析

第 14 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第15章：競爭格局

  • 商業概覽
  • 公司概況
  • 產品與服務
  • 財務（上市公司）
  • 最近的發展
  • SWOT分析
    • Gilead Sciences, Inc.
    • Viatris Inc.
    • Sandoz Inc. (Novartis)
    • Johnson & Johnson
    • Sun Pharmaceutical Industries, Inc.
    • Lupin Pharmaceuticals, Inc.
    • GlaxoSmithKline LLC
    • Johnson & Johnson
    • Bayer AG
    • United Therapeutics Corporation

第 16 章：策略建議

簡介目錄
Product Code: 15927

The Global Pulmonary Arterial Hypertension (PAH) Market reached a valuation of USD 6.66 Billion in 2022 and is expected to experience substantial growth throughout the forecast period, projecting a Compound Annual Growth Rate (CAGR) of 5.32% and expected to reach USD 9.06 Billion through 2028. Pulmonary Arterial Hypertension is a rare but serious medical condition characterized by elevated blood pressure in the pulmonary arteries, which carry blood from the heart to the lungs. This condition leads to the narrowing and stiffening of these arteries, placing increased strain on the heart and potentially resulting in heart failure.

The Global Pulmonary Arterial Hypertension (PAH) Market encompasses various pharmaceuticals, medical devices, and treatment strategies designed to manage and address PAH. Recent developments in medical understanding, innovative therapies, and heightened awareness of PAH have been key drivers of growth in this market. Factors contributing to this growth include the increasing prevalence of PAH due to risk factors like sedentary lifestyles and obesity, as well as improved diagnostic capabilities and heightened awareness among both patients and healthcare professionals.

Pharmaceutical interventions play a pivotal role in managing PAH, with drugs targeting specific pathways associated with the disease's pathogenesis. These medications, such as prostacyclin analogs, endothelin receptor antagonists, and phosphodiesterase type 5 inhibitors, aim to dilate blood vessels, reduce arterial pressure, and alleviate symptoms like fatigue and shortness of breath.

Market Overview
Forecast Period2024-2028
Market Size 2022USD 6.66 Billion
Market Size 2028USD 9.06 Billion
CAGR 2023-20285.32%
Fastest Growing SegmentPhosphodiesterase 5
Largest MarketNorth America

Moreover, medical devices like pulmonary vasodilator pumps and implantable devices like ventricular assist devices contribute to managing severe cases of PAH. Alongside conventional therapies, lifestyle modifications and regular exercise are recommended to enhance patients' quality of life. However, challenges persist within the PAH market, including the high cost of treatment and limited access to specialized care. Additionally, the complexity of PAH diagnosis and the need for specialized expertise can hinder timely intervention.

The outlook of the market is characterized by ongoing research and development efforts focused on discovering novel therapies and improving treatment outcomes. Emerging trends such as personalized medicine approaches, biomarker identification, and combination therapies show promise in tailoring treatments to individual patient needs.

In conclusion, the Global Pulmonary Arterial Hypertension (PAH) Market is undergoing significant transformation due to innovative therapies and medical advancements. As awareness of the condition increases and research continues, the market is poised to witness further developments in diagnostics, treatment options, and patient care, ultimately leading to improved outcomes for those affected by this challenging medical condition.

Key Market Drivers

  • 1. Increasing Prevalence and Awareness of PAH: The rising prevalence of PAH and growing awareness of its severity have driven the expansion of the PAH Market. Public health campaigns, improved medical education, and patient advocacy initiatives have contributed to early diagnosis and intervention.
  • 2. Innovative Therapeutic Approaches: Pharmaceutical advancements targeting PAH's underlying mechanisms have transformed the treatment landscape. Innovative drugs and medical devices are improving patient outcomes and quality of life.
  • 3. Personalized Medicine: Tailoring medical care to individual patient profiles is a significant trend. Genetic testing, molecular profiling, and targeted therapies optimize treatment efficacy and patient engagement.

Key Market Challenges

  • 1. High Treatment Costs: The cost of PAH medications, medical devices, and specialized care poses financial challenges for patients and healthcare systems. Access to effective treatments and comprehensive care can be compromised.
  • 2. Limited Awareness: Lack of awareness among patients and healthcare professionals leads to delayed diagnosis, suboptimal care, and limited research funding. Raising awareness through education and advocacy is crucial.
  • 3. Patent Expiration of Key Drugs: Patent expiration affects treatment accessibility, affordability, and innovation. Balancing patients' access to affordable treatments with pharmaceutical innovation is essential.

Key Market Trends

  • 1. Collaborative Research and Global Networks: International partnerships and networks facilitate knowledge exchange, interdisciplinary approaches, and accelerated development of innovative therapies and treatment guidelines.
  • 2. Personalized Treatment Approaches: Personalized medicine, driven by genetics and molecular profiles, is transforming PAH care. Precise diagnostics and targeted therapies enhance treatment efficacy and patient empowerment.

Segmental Insights

  • 1. Drug Class Insights: Phosphodiesterase 5 inhibitors, such as sildenafil and tadalafil, dominate the PAH Market due to their ability to relax pulmonary blood vessels and alleviate symptoms.
  • 2. Type Insights: Branded medications, with established efficacy and safety records, continue to be the primary choice in PAH treatment, despite the availability of generics.

Regional Insights

North America leads the PAH Market due to advanced healthcare infrastructure, robust research initiatives, and regulatory support. Collaborations among medical institutions, awareness campaigns, and patient advocacy efforts contribute to improved disease management and outcomes in the region.

Key Market Players

  • Gilead Sciences, Inc.
  • Viatris Inc.
  • Sandoz Inc. (Novartis)
  • Johnson & Johnson
  • Sun Pharmaceutical Industries, Inc.
  • Lupin Pharmaceuticals, Inc.
  • GlaxoSmithKline LLC
  • Johnson & Johnson
  • Bayer AG
  • United Therapeutics Corporation

Report Scope:

In this report, the Global Pulmonary Arterial Hypertension Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Pulmonary Arterial Hypertension Market, By Drug Class:

  • Prostacyclin and Prostacyclin Analogs
  • Calcium Channel Blockers
  • Phosphodiesterase 5
  • Endothelin Receptor Antagonist
  • Others

Pulmonary Arterial Hypertension Market, By Type:

  • Branded
  • Generics

Pulmonary Arterial Hypertension Market, By Route Of Administration:

  • Oral
  • Intravenous/ Subcutaneous
  • Inhalational

Global Pulmonary Arterial Hypertension Market, By region:

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Pulmonary Arterial Hypertension Market.

Available Customizations:

  • Global Pulmonary Arterial Hypertension Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customers

5. Global Pulmonary Arterial Hypertension Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class (Prostacyclin and Prostacyclin Analogs, Calcium Channel Blockers, Phosphodiesterase 5, Endothelin Receptor Antagonist and Others)
    • 5.2.2. By Type (Branded, Generics)
    • 5.2.3. By Route Of Administration (Oral, Intravenous/ Subcutaneous, Inhalational)
    • 5.2.4. By Company (2022)
    • 5.2.5. By Region
  • 5.3. Market Map

6. North America Pulmonary Arterial Hypertension Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Type
    • 6.2.3. By Route Of Administration
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Pulmonary Arterial Hypertension Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Type
        • 6.3.1.2.3. By Route Of Administration
    • 6.3.2. Mexico Pulmonary Arterial Hypertension Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Type
        • 6.3.2.2.3. By Route Of Administration
    • 6.3.3. Canada Pulmonary Arterial Hypertension Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Type
        • 6.3.3.2.3. By Route Of Administration

7. Europe Pulmonary Arterial Hypertension Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Type
    • 7.2.3. By Route Of Administration
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Pulmonary Arterial Hypertension Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Type
        • 7.3.1.2.3. By Route Of Administration
    • 7.3.2. Germany Pulmonary Arterial Hypertension Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Type
        • 7.3.2.2.3. By Route Of Administration
    • 7.3.3. United Kingdom Pulmonary Arterial Hypertension Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Type
        • 7.3.3.2.3. By Route Of Administration
    • 7.3.4. Italy Pulmonary Arterial Hypertension Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Type
        • 7.3.4.2.3. By Route Of Administration
    • 7.3.5. Spain Pulmonary Arterial Hypertension Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Type
        • 7.3.5.2.3. By Route Of Administration

8. Asia-Pacific Pulmonary Arterial Hypertension Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Type
    • 8.2.3. By Route Of Administration
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Pulmonary Arterial Hypertension Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Type
        • 8.3.1.2.3. By Route Of Administration
    • 8.3.2. India Pulmonary Arterial Hypertension Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Type
        • 8.3.2.2.3. By Route Of Administration
    • 8.3.3. South Korea Pulmonary Arterial Hypertension Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Type
        • 8.3.3.2.3. By Route Of Administration
    • 8.3.4. Japan Pulmonary Arterial Hypertension Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Type
        • 8.3.4.2.3. By Route Of Administration
    • 8.3.5. Australia Pulmonary Arterial Hypertension Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Type
        • 8.3.5.2.3. By Route Of Administration

9. South America Pulmonary Arterial Hypertension Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Type
    • 9.2.3. By Route Of Administration
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Pulmonary Arterial Hypertension Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Type
        • 9.3.1.2.3. By Route Of Administration
    • 9.3.2. Argentina Pulmonary Arterial Hypertension Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Type
        • 9.3.2.2.3. By Route Of Administration
    • 9.3.3. Colombia Pulmonary Arterial Hypertension Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Type
        • 9.3.3.2.3. By Route Of Administration

10. Middle East and Africa Pulmonary Arterial Hypertension Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Type
    • 10.2.3. By Route Of Administration
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Pulmonary Arterial Hypertension Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Type
        • 10.3.1.2.3. By Route Of Administration
    • 10.3.2. Saudi Arabia Pulmonary Arterial Hypertension Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Type
        • 10.3.2.2.3. By Route Of Administration
    • 10.3.3. UAE Pulmonary Arterial Hypertension Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Type
        • 10.3.3.2.3. By Route Of Administration

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Company Snapshot
  • 15.3. Product & Services
  • 15.4. Financials (In case of listed companies)
  • 15.5. Recent Developments
  • 15.6. SWOT Analysis
    • 15.6.1. Gilead Sciences, Inc.
    • 15.6.2. Viatris Inc.
    • 15.6.3. Sandoz Inc. (Novartis)
    • 15.6.4. Johnson & Johnson
    • 15.6.5. Sun Pharmaceutical Industries, Inc.
    • 15.6.6. Lupin Pharmaceuticals, Inc.
    • 15.6.7. GlaxoSmithKline LLC
    • 15.6.8. Johnson & Johnson
    • 15.6.9. Bayer AG
    • 15.6.10. United Therapeutics Corporation

16. Strategic Recommendations